XELOX与FOLFOX6应用于晚期结直肠癌治疗的临床观察

Clinical Observation of XELOX and FOLFOX6 in the Treatment of Advanced Colorectal Cancer

目的探讨卡培他滨+奥沙利铂(XELOX)化疗方案与亚叶酸钙/5-氟脲嘧啶+奥沙利铂(FOLFOX6)化疗方案治疗晚期结直肠癌的近期疗效、不良反应及远期生存率的影响。方法选取106例晚期结直肠癌患者为研究对象,其中接受XELOX化疗方案者57例,接受FOLFOX6方案者49例。对比2组治疗总疗效、不良反应发生情况以及生存率。结果治疗后,XELOX组总有效率为56.14%,FOLFOX6组总有效率为53.06%,2组差异无统计学意义(P>0.05)。XELOX化疗组手足综合征发生率为14.04%,明显高于FOLFOX6化疗组发生率2.04%,差异有统计学意义(P<0.05),但其程度较轻,主要以Ⅰ~Ⅱ度为主;FOLFOX6化疗组神经毒性发生率为22.45%,明显高于XELOX化疗组发生率5.26%(P<0.05),程度较轻,主要以Ⅰ~Ⅱ度为主;2组在白细胞减少、恶心、呕吐、口腔炎、脱发等发生率上比较,差异无统计学意义(P>0.05)。XELOX组疾病无进展生存时间中位数为15个月,FOLFOX6组17个月;XELOX化疗组1年生存率为85.96%,高于FOLFOX6化疗组1年生存率83.67%,但差异无统计学意义(P>0.05)。结论 XELOX与FOLFOX6化疗方案治疗晚期结直肠癌的疗效相当,但XELOX化疗方案用药更为安全方便。

Objective To investigate the effect of XELOX chemotherapy regimen and FOLFOX6 chemotherapy regimen on short-term efficacy,adverse reaction and long-term survival rate in patients with advanced eolorectal cancer. Methods 106 patients with advanced eoloreetal cancer were selected as the study subjects,including 57 patients received XELOX chemotherapy regimen ,49 patients received FOLFOX6 regimen. Comparison of the total treatment of two groups, the incidence of adverse reac- tions and survival rate. Results After treatment,the total effective rate of XELOX group was 56.14% ,the total effective rate of FOLFOX6 group was 53.06% ,and the difference was not statistically significant （P 〉 0.05） ;The incidence of hand-foot syn- drome in XELOX chemotherapy group was 14.04% , which was significantly higher than that in FOLFOX6 chemotherapy group （2.04%）, the difference was statistically significant （P 〈 0.05 ）, but it was mainly I-II degree. The incidence of neurotoxicity in FOLFOX6 chemotherapy group was 22. 45% , which was significantly higher than that in XELOX chemotherapy group （5.26% ,P 〈0. 05 ）, and it was mainly I - II degree. There was no significant difference between the two groups in the inci- dence of leukopenia, nausea, vomiting, stomatitis and hair loss （ P 〉 0.05 ）. The median survival time of non-progression of XE- LOX group was 15 months, FOLFOX6 group was 17 months; The 1-year survival rate was 85.96% in the XELOX chemotherapy group, which was higher than that in the FOLFOX6 chemotherapy group （83.67%） , but the difference was not statistically signifi- cant （ P 〉 0.05 ）. Conclusion XELOX and FOLFOX6 chemotherapy in the treatment of advanced colorectal cancer have the same effect,but XELOX program more secure and convenient.